Introduction
hyperuricemia
ADVERSE EVENTS, HYPERURICEMIA
Over 20% of people in high-income countries have been affected by hyperuricemiaDrugs for hyperuricemia treatment include xanthine oxidase inhibitors (XOIs), which block urate production, and uricosuric drugs, which promote the urinary excretion of UA. Allopurinol and febuxostat are the commonly used XOIs. However, the target serum UA level (serum UA ≤ 360 μmol/L) cannot be achieved in over 30% of patients with hyperuricemia who receive XOI aloneHP501, a highly selective URAT1 inhibitor, was developed by Hinova Pharmaceuticals, Inc. (Chengdu, China). During phase I/IIa trial that enrolled 68 healthy volunteers and 36 patients with hyperuricemia, HP501 significantly reduced serum UA levels with low incidence of adverse events (AEs)